IRLAB Therapeutics AB

IRLAB A

SE0012675361

IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâs disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâs Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Sector

Pharmaceuticals

Calendar

22/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for IRLAB Therapeutics AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IRLAB THERAPEUTICS AB	+74.00%	62.46M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 08:59:46 10/05/2024 pm IST			5-day change	1st Jan Change
13.05 ^SEK	+13.48%		+19.18%	+74.00%

08/05	Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024
07/05	IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	CI

Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024	08/05
IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	07/05	CI
IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757	06/05	CI
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	22/03	CI
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	19/03	CI
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	22/02	CI
Transcript : IRLAB Therapeutics AB, 2023 Earnings Call, Feb 07, 2024	07/02
IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07/02	CI
IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines	06/02	CI
IRLAB Therapeutics AB(OM:IRLAB A) added to OMX Nordic Small Cap Index	04/01	CI
Irlab Therapeutics to Meet with US FDA for Mesdopetam Progam in February	03/01	MT
IRLAB Is Granted an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	03/01	CI
IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I	21/12	CI
IRLAB Therapeutics AB Receives Grant from the Michael J. Fox Foundation to Support Development of IRL 757 for the Treatment of Apathy	21/12	CI
IRLAB Therapeutics AB Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	18/12	CI
Irlab Therapeutics Secures European Patent for Parkinson’s Disease Drug Candidate	12/12	MT
IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection	12/12	CI
IRLAB Therapeutics AB Announces Appointment to its Nomination Committee	07/11	CI
Transcript : IRLAB Therapeutics AB, Nine Months 2023 Earnings Call, Oct 25, 2023	25/23/25
IRLAB Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	25/23/25	CI
Transcript : IRLAB Therapeutics AB - Analyst/Investor Day	17/23/17
Transcript : IRLAB Therapeutics AB Presents at Redeye Neurology Seminar, Oct-11-2023 10:10 AM	11/23/11
IRLAB Therapeutics AB Signs With Clintrex and ProPharma Group Phase III Regulatory US Consultants to Support Preparation for Mesdopetam?s end-of-Phase 2 Meeting with the US FDA	10/23/10	CI
Transcript : IRLAB Therapeutics AB, Q2 2023 Earnings Call, Aug 30, 2023	30/23/30
IRLAB Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/23/30	CI

IRLAB Therapeutics AB

Equities